STAR TANGYIE-CHE NIBA: Open Payments
NPI 1679835698 · COLUMBIA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$378 in 14 payments from 6 companies in 2025. Trend: 2023 $269 · 2024 $107 · 2025 $378
Food & beverage: $378
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 5 | $156 |
| Vanda Pharmaceuticals Inc. | 2 | $74 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| E.R. Squibb & Sons, L.L.C. | 3 | $51 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
| Lundbeck LLC | 1 | $17 |
Products named: INGREZZA, FANAPT, Auvelity, COBENFY, CAPLYTA, REXULTI.
Industry payments across MD — which companies pay providers there.
